Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics

Core Insights - Wall Street analysts forecast that Globus Medical (GMED) will report quarterly earnings of $0.76 per share, reflecting a year-over-year increase of 1.3% and revenues of $741.7 million, which is an increase of 17.8% compared to the previous year [1] Earnings Estimates - Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, indicating a collective reconsideration by covering analysts [2] - Changes in earnings estimates are crucial for predicting potential investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts project 'Net Sales by Product Category- Enabling Technologies' at $37.43 million, suggesting a year-over-year change of +1.8% [5] - The consensus estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' is $679.67 million, indicating a year-over-year change of +14.6% [5] - 'Geographic Revenues- International' is expected to reach $140.52 million, reflecting a change of +7.9% from the year-ago quarter [5] - 'Geographic Revenues- United States' is projected to be $586.71 million, suggesting a year-over-year change of +17.5% [6] Stock Performance - Shares of Globus Medical have experienced a change of -5.2% in the past month, contrasting with the +0.5% move of the Zacks S&P 500 composite [6] - With a Zacks Rank 4 (Sell), GMED is expected to underperform the overall market in the near future [6]